Health care and technology are the two sectors where investors looking for growth typically look first.

But which stocks are both alluring -- when it comes to rapid advances in new technology or a cure for a disease, for instance -- but also sound investments?

The stocks on this list are all buy-recommended health care stocks with either A or A+ ratings by TheStreet Ratings, TheStreet's proprietary ratings tool. TheStreet included trailing 12-month revenue growth, net income growth and EPS growth on each company for comparison. And when you're done be sure to check out the 12 high-growth tech stocks to buy for 2016.

TheStreet Ratings uses a quantitative approach to rating over 4,300 stocks to predict return potential for the next year. The model is both objective, using elements such as volatility of past operating revenues, financial strength, and company cash flows, and subjective, including expected equities market returns, future interest rates, implied industry outlook and forecasted company earnings.

Buying an S&P 500 stock that TheStreet Ratings rated a "buy" yielded a 16.56% return in 2014 beating the S&P 500 Total Return Index by 304 basis points. Buying a Russell 2000 stock that TheStreet Ratings rated a "buy" yielded a 9.5% return in 2014, beating the Russell 2000 index, including dividends reinvested, by 460 basis points last year.

Image placeholder title

AMSG

data by

YCharts

1. AmSurg Corp. (AMSG)
Industry: Health Care/Health Care Facilities
Market Cap: $4 billion
Year-to-date Return: 52.8%

AmSurg Corp., through its subsidiaries, provides ambulatory and physician services in the United States. The company operates through two divisions, Ambulatory Services and Physician Services.

12-Month Revenue Growth: 85.29%
12-Month Net Income Growth: 171.91%
12-Month EPS Growth: 62.16%

TheStreet Said: TheStreet Ratings team rates AMSURG CORP as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:

We rate AMSURG CORP (AMSG) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income, good cash flow from operations, solid stock price performance and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • The revenue growth came in higher than the industry average of 10.2%. Since the same quarter one year prior, revenues rose by 29.4%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Providers & Services industry. The net income increased by 533.8% when compared to the same quarter one year prior, rising from -$9.83 million to $42.66 million.
  • Net operating cash flow has increased to $175.81 million or 43.55% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of 11.26%.
  • Powered by its strong earnings growth of 460.86% and other important driving factors, this stock has surged by 60.19% over the past year, outperforming the rise in the S&P 500 Index during the same period. We feel that the stock's sharp appreciation over the last year has driven it to a price level which is now somewhat expensive compared to the rest of its industry. The other strengths this company shows, however, justify the higher price levels.
  • AMSURG CORP reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, AMSURG CORP reported lower earnings of $1.42 versus $2.22 in the prior year. This year, the market expects an improvement in earnings ($3.68 versus $1.42).
  • You can view the full analysis from the report here: AMSG
Image placeholder title

BABY

data by

YCharts

2. Natus Medical Inc. (BABY)
Industry: Health Care/Health Care Equipment
Market Cap: $1.5 billion
Year-to-date Return: 29.6%

Natus Medical Incorporated designs, manufactures, and markets newborn care and neurology healthcare products and services worldwide.

12-Month Revenue Growth: 4.95%
12-Month Net Income Growth: 27.41%
12-Month EPS Growth: 24.74%

TheStreet Said: TheStreet Ratings team rates NATUS MEDICAL INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:

We rate NATUS MEDICAL INC (BABY) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • Powered by its strong earnings growth of 37.50% and other important driving factors, this stock has surged by 35.43% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the stock's future course, although almost any stock can fall in a broad market decline, BABY should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
  • NATUS MEDICAL INC has improved earnings per share by 37.5% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, NATUS MEDICAL INC increased its bottom line by earning $1.00 versus $0.74 in the prior year. This year, the market expects an improvement in earnings ($1.52 versus $1.00).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 39.8% when compared to the same quarter one year prior, rising from $7.82 million to $10.93 million.
  • The revenue growth significantly trails the industry average of 37.8%. Since the same quarter one year prior, revenues slightly increased by 5.2%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • BABY has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. To add to this, BABY has a quick ratio of 2.33, which demonstrates the ability of the company to cover short-term liquidity needs.
  • You can view the full analysis from the report here: BABY
Image placeholder title

CHE

data by

YCharts

3. Chemed Corp. (CHE) - Get Report
Industry: Health Care/Health Care Services
Market Cap: $2.5 billion
Year-to-date Return: 40.8%

Chemed Corporation provides hospice and palliative care services in the United States. It operates in two segments, VITAS and Roto-Rooter. The company offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.

12-Month Revenue Growth: 6.92%
12-Month Net Income Growth: 19.15%
12-Month EPS Growth: 22.52%

TheStreet Said: TheStreet Ratings team rates CHEMED CORP as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:

We rate CHEMED CORP (CHE) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, notable return on equity and good cash flow from operations. We feel its strengths outweigh the fact that the company shows low profit margins.

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • CHEMED CORP has improved earnings per share by 18.7% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, CHEMED CORP increased its bottom line by earning $5.58 versus $4.16 in the prior year. This year, the market expects an improvement in earnings ($6.80 versus $5.58).
  • The company, on the basis of net income growth from the same quarter one year ago, has significantly outperformed against the S&P 500 and exceeded that of the Health Care Providers & Services industry average. The net income increased by 17.3% when compared to the same quarter one year prior, going from $24.59 million to $28.83 million.
  • Despite its growing revenue, the company underperformed as compared with the industry average of 10.2%. Since the same quarter one year prior, revenues slightly increased by 7.8%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Health Care Providers & Services industry and the overall market, CHEMED CORP's return on equity exceeds that of both the industry average and the S&P 500.
  • Net operating cash flow has significantly increased by 636.87% to $43.45 million when compared to the same quarter last year. In addition, CHEMED CORP has also vastly surpassed the industry average cash flow growth rate of 11.26%.
  • You can view the full analysis from the report here: CHE
Image placeholder title

ICLR

data by

YCharts

4. ICON Public Limited Co. (ICLR) - Get Report
Industry: Health Care/Life Sciences Tools & Services
Market Cap: $3.8 billion
Year-to-date Return: 33.3%

ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally.

12-Month Revenue Growth: 7.07%
12-Month Net Income Growth: 37.56%
12-Month EPS Growth: 42.29%

TheStreet Said: TheStreet Ratings team rates ICON PLC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:

We rate ICON PLC (ICLR) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • ICLR's revenue growth has slightly outpaced the industry average of 5.4%. Since the same quarter one year prior, revenues slightly increased by 1.8%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • The current debt-to-equity ratio, 0.41, is low and is below the industry average, implying that there has been successful management of debt levels.
  • Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. When compared to other companies in the Life Sciences Tools & Services industry and the overall market, ICON PLC's return on equity exceeds that of the industry average and significantly exceeds that of the S&P 500.
  • 42.61% is the gross profit margin for ICON PLC which we consider to be strong. It has increased from the same quarter the previous year. Along with this, the net profit margin of 15.59% is above that of the industry average.
  • You can view the full analysis from the report here: ICLR
Image placeholder title

LMAT

data by

YCharts

5. LeMaitre Vascular Inc. (LMAT) - Get Report
Industry: Health Care/Health Care Equipment
Market Cap: $251 million
Year-to-date Return: 85.5%

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants for the treatment of peripheral vascular disease worldwide.

12-Month Revenue Growth: 8.84%
12-Month Net Income Growth: 160.25%
12-Month EPS Growth: 135.29%

TheStreet Said: TheStreet Ratings team rates LEMAITRE VASCULAR INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:

We rate LEMAITRE VASCULAR INC (LMAT) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • Powered by its strong earnings growth of 120.00% and other important driving factors, this stock has surged by 90.05% over the past year, outperforming the rise in the S&P 500 Index during the same period. Turning to the future, naturally, any stock can fall in a major bear market. However, in almost any other environment, the stock should continue to move higher despite the fact that it has already enjoyed nice gains in the past year.
  • LEMAITRE VASCULAR INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, LEMAITRE VASCULAR INC increased its bottom line by earning $0.23 versus $0.21 in the prior year. This year, the market expects an improvement in earnings ($0.38 versus $0.23).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 124.0% when compared to the same quarter one year prior, rising from $0.93 million to $2.09 million.
  • LMAT's revenue growth trails the industry average of 37.8%. Since the same quarter one year prior, revenues slightly increased by 8.7%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • LMAT has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 3.96, which clearly demonstrates the ability to cover short-term cash needs.
  • You can view the full analysis from the report here: LMAT
Image placeholder title

MD

data by

YCharts

6. Mednax Inc. (MD) - Get Report
Industry: Health Care/Health Care Services
Market Cap: $6.7 billion
Year-to-date Return: 8.6%

MEDNAX, Inc., together with its subsidiaries, provides neonatal, anesthesia, maternal-fetal, and other pediatric subspecialties physician services in the United States and Puerto Rico.

12-Month Revenue Growth: 14.13%
12-Month Net Income Growth: 7.84%
12-Month EPS Growth: 13.72%

TheStreet Said: TheStreet Ratings team rates MEDNAX INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:

We rate MEDNAX INC (MD) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, increase in net income and solid stock price performance. We feel its strengths outweigh the fact that the company shows low profit margins.

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • MD's revenue growth has slightly outpaced the industry average of 10.2%. Since the same quarter one year prior, revenues rose by 15.3%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • The current debt-to-equity ratio, 0.58, is low and is below the industry average, implying that there has been successful management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.18, which illustrates the ability to avoid short-term cash problems.
  • MEDNAX INC has improved earnings per share by 12.8% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, MEDNAX INC increased its bottom line by earning $3.17 versus $2.78 in the prior year. This year, the market expects an improvement in earnings ($4.07 versus $3.17).
  • The net income growth from the same quarter one year ago has greatly exceeded that of the S&P 500, but is less than that of the Health Care Providers & Services industry average. The net income increased by 5.3% when compared to the same quarter one year prior, going from $86.21 million to $90.78 million.
  • The stock has not only risen over the past year, it has done so at a faster pace than the S&P 500, reflecting the earnings growth and other positive factors similar to those we have cited here. The stock's price rise over the last year has driven it to a level which is somewhat expensive compared to the rest of its industry. We feel, however, that other strengths this company displays justify these higher price levels.
  • You can view the full analysis from the report here: MD
Image placeholder title

SIRO

data by

YCharts

7. Sirona Dental Systems Inc. (SIRO)
Industry: Health Care/Health Care Equipment
Market Cap: $6 billion
Year-to-date Return: 23.3%

Sirona Dental Systems, Inc. develops, manufactures, and markets dental equipment for dentists worldwide. It operates through four segments Dental CAD/CAM Systems, Imaging Systems, Treatment Centers, and Instruments.

12-Month Revenue Growth: -1.15%
12-Month Net Income Growth: 8.42%
12-Month EPS Growth: 7.94%

TheStreet Said: TheStreet Ratings team rates SIRONA DENTAL SYSTEMS INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:

We rate SIRONA DENTAL SYSTEMS INC (SIRO) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • Investors have apparently begun to recognize positive factors similar to those we have mentioned in this report, including earnings growth. This has helped drive up the company's shares by a sharp 28.21% over the past year, a rise that has exceeded that of the S&P 500 Index. Regarding the stock's future course, although almost any stock can fall in a broad market decline, SIRO should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
  • SIRONA DENTAL SYSTEMS INC has improved earnings per share by 13.0% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, SIRONA DENTAL SYSTEMS INC increased its bottom line by earning $3.13 versus $2.61 in the prior year. This year, the market expects an improvement in earnings ($3.96 versus $3.13).
  • The company, on the basis of net income growth from the same quarter one year ago, has significantly outperformed against the S&P 500 and exceeded that of the Health Care Equipment & Supplies industry average. The net income increased by 14.2% when compared to the same quarter one year prior, going from $51.50 million to $58.80 million.
  • The revenue growth significantly trails the industry average of 37.8%. Since the same quarter one year prior, revenues slightly increased by 2.1%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • SIRO's debt-to-equity ratio is very low at 0.06 and is currently below that of the industry average, implying that there has been very successful management of debt levels. To add to this, SIRO has a quick ratio of 2.12, which demonstrates the ability of the company to cover short-term liquidity needs.
  • You can view the full analysis from the report here: SIRO
Image placeholder title

SLP

data by

YCharts

8. Simulations Plus Inc. (SLP) - Get Report
Industry: Health Care/Health Care Technology
Market Cap: $150 million
Year-to-date Return: 30.2%

Simulations Plus, Inc. designs and develops pharmaceutical simulation software for use in pharmaceutical research, and in the education of pharmacy and medical students.

12-Month Revenue Growth: 50.48%
12-Month Net Income Growth: 17.25%
12-Month EPS Growth: 10.52%

TheStreet Said: TheStreet Ratings team rates SIMULATIONS PLUS INC as a Buy with a ratings score of A+. TheStreet Ratings Team has this to say about their recommendation:

We rate SIMULATIONS PLUS INC (SLP) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • SLP's very impressive revenue growth greatly exceeded the industry average of 27.1%. Since the same quarter one year prior, revenues leaped by 58.8%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.
  • SLP has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 6.61, which clearly demonstrates the ability to cover short-term cash needs.
  • Powered by its strong earnings growth of 37.50% and other important driving factors, this stock has surged by 34.60% over the past year, outperforming the rise in the S&P 500 Index during the same period. Regarding the stock's future course, although almost any stock can fall in a broad market decline, SLP should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
  • The gross profit margin for SIMULATIONS PLUS INC is currently very high, coming in at 88.34%. It has increased significantly from the same period last year. Along with this, the net profit margin of 31.18% significantly outperformed against the industry average.
  • Net operating cash flow has increased to $2.14 million or 26.78% when compared to the same quarter last year. The firm also exceeded the industry average cash flow growth rate of 7.26%.
  • You can view the full analysis from the report here: SLP

UHS data by YCharts
9. Universal Health Services Inc. (UHS) - Get Report
Industry: Health Care/Health Care Facilities
Market Cap: $11.9 billion
Year-to-date Return: 10.3%

Image placeholder title

Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers.

12-Month Revenue Growth: 12.85%
12-Month Net Income Growth: 36.71%
12-Month EPS Growth: 35.75%

TheStreet Said: TheStreet Ratings team rates UNIVERSAL HEALTH SVCS INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:

We rate UNIVERSAL HEALTH SVCS INC (UHS) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows low profit margins.

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period. Although other factors naturally played a role, the company's strong earnings growth was key. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
  • UNIVERSAL HEALTH SVCS INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, UNIVERSAL HEALTH SVCS INC increased its bottom line by earning $5.42 versus $5.13 in the prior year. This year, the market expects an improvement in earnings ($6.91 versus $5.42).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Providers & Services industry. The net income increased by 81.5% when compared to the same quarter one year prior, rising from $82.80 million to $150.29 million.
  • Despite its growing revenue, the company underperformed as compared with the industry average of 10.2%. Since the same quarter one year prior, revenues slightly increased by 9.3%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • The debt-to-equity ratio is somewhat low, currently at 0.75, and is less than that of the industry average, implying that there has been a relatively successful effort in the management of debt levels. Along with the favorable debt-to-equity ratio, the company maintains an adequate quick ratio of 1.14, which illustrates the ability to avoid short-term cash problems.
  • You can view the full analysis from the report here: UHS
Image placeholder title

WOOF

data by

YCharts

10. VCA Inc. (WOOF)
Industry: Health Care/Health Care Facilities
Market Cap: $4.3 billion
Year-to-date Return: 11.8%

VCA Inc. operates as an animal healthcare company in the United States and Canada. It operates through Animal Hospital and Laboratory segments.

12-Month Revenue Growth: 10.98%
12-Month Net Income Growth: 33.39%
12-Month EPS Growth: 42.56%

TheStreet Said: TheStreet Ratings team rates VCA INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:

We rate VCA INC (WOOF) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, good cash flow from operations, compelling growth in net income and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company shows low profit margins.

Highlights from the analysis by TheStreet Ratings Team goes as follows:

  • WOOF's revenue growth has slightly outpaced the industry average of 10.2%. Since the same quarter one year prior, revenues rose by 10.4%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Health Care Providers & Services industry and the overall market, VCA INC's return on equity exceeds that of both the industry average and the S&P 500.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Providers & Services industry. The net income increased by 99.8% when compared to the same quarter one year prior, rising from $27.45 million to $54.85 million.
  • Net operating cash flow has increased to $117.26 million or 20.96% when compared to the same quarter last year. In addition, VCA INC has also modestly surpassed the industry average cash flow growth rate of 11.26%.
  • VCA INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. Stable earnings per share over the past year indicate the company has sound management over its earnings and share float. We anticipate these figures will begin to experience more growth in the coming year. During the past fiscal year, VCA INC's EPS of $1.53 remained unchanged from the prior years' EPS of $1.53. This year, the market expects an improvement in earnings ($2.33 versus $1.53).
  • You can view the full analysis from the report here: WOOF